FRACTYL HEALTH, INC.
Public company- Headquarters
- BURLINGTON, Massachusetts
- Ticker
- GUTS
- CIK
- 0001572616
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III directorMichael Wartell | Nov 6, 2026 | Appointed |
| President and Chief Product OfficerJay Caplan | Oct 22, 2026 | Departed |
| PresidentHarith Rajagopalan, M.D., Ph.D. | Oct 22, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- LEMAITRE VASCULAR INC
President departs: David B. Roberts
- BOSTON SCIENTIFIC CORP
COO appointed: Joe Fitzgerald
- INSULET CORP
member of the Board of Directors departs: Timothy J. Scannell
- HAEMONETICS CORP
Plant closure: CA
- Executive appointment
Class III director appointed: Michael Wartell
Michael Wartell was named Class III director of FRACTYL HEALTH, INC., effective November 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Nov 6, 2026Role: Class III director
- Executive departure
President and Chief Product Officer departs: Jay Caplan
Jay Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC., retires the role, effective October 30, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 22, 2026Role: President and Chief Product Officer
- Executive appointment
President appointed: Harith Rajagopalan, M.D., Ph.D.
Harith Rajagopalan, M.D., Ph.D. was named President of FRACTYL HEALTH, INC., effective October 30, 2026. Harith Rajagopalan, M.D., Ph.D. succeeds Jay Caplan. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 22, 2026Role: President
Last verified Nov 8, 2026